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Background/aim: Familial Mediterranean fever (FMF), the most common autoinflammatory disease in children, is characterized by
recurrent febrile episodes. FMF is known to progress with chronic inflammation, particularly during attack periods. This study aimed to
investigate the relationship of S100A12, an inflammatory marker, with attacks and inflammatory events in FMF patients.
Materials and methods: The study included 57 patients diagnosed with FMF, 43 in an attack-free period and 14 in an attack period, and
31 healthy children as the control group. Only white blood cell (WBC) count, C-reactive protein (CRP) level, erythrocyte sedimentation
rate (ESR), and S100A12 level were analyzed in the control group. In addition, serum amyloid A (SAA), and fibrinogen levels were
measured, and a mutation analysis was performed in the patient group. The results were compared among the attack-free period, acute
attack FMF and control groups.
Results: The mean age of patients and control group was 10 (2.5–18) and 9.5 (2.5–16) years, respectively. The CRP (p = 0.001), S100A12
(p = 0.003) and ESR (p= 0.001) values differed significantly between the FMF and control groups. S100A12 level (p = 0.027), WBC count
(p = 0.003), CRP level (p = 0.0001), ESR (p = 0.004), and fibrinogen level (p = 0.001) differed significantly between the acute attack and
attack-free period groups. SAA level (p = 0.05), ESR (p = 0.001), fibrinogen level (p = 0.001), WBC count (p = 0.001), and S100A12 level
(p = 0.027) were higher in M694V homozygous FMF patients than in other FMF patients.
Conclusion: Patients with FMF had higher S100A12 levels than the control group, while the mean S100A12 concentration was higher
in acute attack period patients than in attack-free period patients. S100A12 level might be an important indicator in the monitoring of
chronic inflammation in patients with FMF.
Key words: Children, familial Mediterranean fever, inflammation, S100A12

1. Introduction
Familial Mediterranean fever (FMF) is a self-limited,
autosomal-recessive
autoinflammatory
disease,
characterized by recurrent febrile attacks and sterile
polyserositis [1–4]. The Mediterranean Fever (MEFV) gene,
which is localized on the chromosome 16p13.3, causes FMF,
which is prevalent in the Eastern Mediterranean region [5].
Various MEFV mutations are known to cause FMF (M694V,
E148Q, M694I, V726A, and M680I), but the most severe is
reportedly a homozygous M694V mutation [2–4,6]. Defects
in the MEFV gene lead to a pro-inflammatory response
via interleukin-β by disrupting the synthesis of pyrin
(marenostrin), which regulates neutrophil activity [7,8].
FMF is a disease that typically achieves clinical
quiescence between irregular acute febrile episodes. There

may be episodes with and without acute attacks in the
course of FMF. Serum amyloid A (SAA), an acute-phase
reactant produced in response to infection, inflammation,
and trauma, is primarily synthesized in the liver. During
the acute febrile attacks, an increase in biologically acute
phase reactants such as white blood cell (WBC) count,
C-reactive protein (CRP), erythrocyte sedimentation
rate (ESR), and SAA can be observed. Diagnosing FMF
becomes difficult due to the absence of a specific laboratory
test, and findings that mimic infections, malignancies,
and other autoimmune diseases [2–4,6]. The diagnosis
and treatment are delayed due to an increase in similar
inflammatory laboratory parameters (WBC count, CRP,
ESR, and SAA); hence, there is a need for other diagnostic
tests.

* Correspondence: yldtrkmngl@hotmail.com

1396

This work is licensed under a Creative Commons Attribution 4.0 International License.

TÜRKMENOĞLU et al. / Turk J Med Sci
S100 proteins is a group of proinflammatory mediators
released from human neutrophils that belong to a Ca+binding protein family. The S100 proteins exhibit cytokinelike extracellular functions. The phagocyte-specific S100
proteins are known as A8, A9, and A12 (calgranulin C) and
are released from monocytes and granulocytes. S100A12
is a member of the damage-associated molecular pattern
molecule family and these proteins, after being released from
activated or necrotic cells, induce an inflammatory response
and the accumulation of immune cells in the damaged tissue
[9]. The S100A12 gene is approximately 4.1 kilobase pairs
(kbp) long and consists of three exons, which are divided
by 900 and 400 bp introns. The first exon is untranslated and
comprises 48 nucleotides. A classical TATA box (TATAAA)
is located 30 nucleotides upstream of the transcription
initiation site. The protein is encoded by sequences in exons
2 (138 nucleotides) and 3 (138 nucleotides). S100A12 is
generally expressed by granulocytes and acts on the receptor
for advanced glycation end products. The activation of this
receptor induces the proinflammatory response via nuclear
factor-kappa B in leukocytes and endothelial cells, and this
protein is reportedly a marker for granulocyte activation that
is more useful than CRP and ESR for detecting inflammatory
activity. The amount of S100A12 protein is also known to
increase in cases of malignancies, obstructive sleep apnea,
autoimmune diseases, systemic lupus erythematosus,
juvenile arthritis, and FMF [10–14].
The primary purpose of this study was to determine the
relationship between S100A12 and chronic inflammation
in children with FMF. The secondary purpose was to
determine the association between S100A12 protein and
other inflammation markers during the attack and attackfree periods as well as the association between this protein
and other inflammatory markers in the attack period with
the mutation findings.
2. Materials and methods
2.1. Study design
A- case control study with a nested cross-sectional
assessment of acute attack period effects was performed at
the Okmeydanı Training and Research Hospital between
February 1, 2019 and July 1, 2019. Written approval was
obtained from the local ethics committee of our hospital
prior to the study, which was performed in accordance with
the principles of the World Medical Association Declaration
of Helsinki. The participants or their families were informed
about the aims and scope of the research. Written informed
consent was obtained from patients and their parents if the
patient was older than 9 years or only from the parents if the
patient was younger.
2.2. Patient populations
The study group initially consisted of 64 children with
FMF aged 2.5–18 years who were followed up in our

hospital’s pediatric nephrology outpatient clinic. We
included healthy 36 children, who applied to the Pediatric
Outpatient Clinic of our hospital for routine examination
and had no history of fever, infection, malignancy, known
chronic disease or drug use, as the control group. Seven
patients and 5 healthy children with for whom patient
records or laboratory tests were missing were excluded
from the study. Overall, the study sample consisted of 88
individuals: (57 patients and 31 healthy controls).
The Tel-Hashomer criteria were used to diagnose FMF
[2–4,6,15]. Patients taking anti-inflammatory medications
and anticoagulants, and those over 18 years or under 2.5
years old were excluded from the study. FMF patients were
divided into two groups: attack-free patients and those in
the attack period. Patients with joint, chest, or abdominal
pain of unknown origin on the day of sample collection
were considered attack FMF patients regardless of their
laboratory values. Detailed stories of all patients were
recorded, and the body mass indexes were calculated.
Colchicine dosage and other treatments received by the
patients were noted. In addition, the genetic analysis
results of the FMF patients were examined.
2.3. Laboratory tests
Blood samples were drawn to determine WBC count,
CRP levels, ESR, and S100A12 level of individuals in the
control group. In addition, SAA and fibrinogen levels were
determined and mutation analyses were performed in the
FMF group.
Genetic analysis:
Peripheral blood samples were used for DNA
isolation. Two milliliters of peripheral blood was
collected into an EDTA tube for DNA isolation. The
DNA obtained was amplified by polymerase chain
reaction (PCR) using primers specific for exon 2
(forward (F): 5′-GAGCAAACGCAGAGAGAAGG-3′
and reverse (R): 5′-TAGGTCGCATCTTTCCCGAG-3′),
exon 3 (F: 5′-GTCCAGCTGCTCTTCTGTGA-3′,
R:
5′-CTGCCTTCTCCTCCCCATAG-3′),
exon
5
(F:
5′-ATGGTTGGGCAGATCAGGAA-3′,
R:
5′-CACTTTTCAGGGACAGGCAC-3′)
and
exon
10(F:5′-AAATGAGTACCAGGCGTCCA-3′, and R:5′AGGAGCTGTGTTCTTCCCTC-3′) sequences of the
MEFV gene (Gene ID: 4210). The resulting fragments
were sequenced using next generation sequencing for
mutation analysis.
For the S100A12 measurement, Elabscience Human
ELISA kits (Shanghai, China, 2019) were used. For the
S100A12 test, 5 mL blood samples were taken from FMF
patients and healthy controls, centrifuged in a 4000RPM centrifuge for 10 min to obtain serum samples and
stored at (–80) ºC until the study. All frozen samples were
thawed at room temperature for the S100A12 test, and the
ELISA kits were used to quantify serum human S100A12
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protein concentrations and the results were recorded in
nanograms per milliliter.
2.4. Statistical analyses
The statistical analysis was performed using SPSS software
(v:17.0; SPSS Inc., Chicago, IL, USA). If the distribution of
the continuous variables was normal, they were presented
as mean ± SD (p > 0.05 on the Kolmogorov–Smirnov or
Shapiro–Wilk test; (n < 30)). If the continuous variables
were not normally distributed, they were described as
the median (min-max). Intergroup comparisons were
analyzed using Student’s t-test variance for normally
distributed data, while the Mann–Whitney U test were
used to examine non-normally distributed data. Receiver
operating characteristic (ROC) curves were constructed
and the areas under curve (AUC) and the sensitivity
(sen.), and the specificity (spe.) were calculated. Spearman
correlation test was used to examine the relationship
between variables in the groups p-values < 0.05, were
considered statistically significant.
3. Results
The mean FMF patient age was 10 (2.5–18) years, while
that of the controls was 9.5 (2.5–16) years. There was
no statistically significant intergroup difference in age
(p = 0.808). The clinical findings of the 57 FMF patients
included in the study are shown in Table 1. The patient
group consisted of 31 (54.4%) boys, whereas the control
group consisted of 13 (41.9%) boys. There was no
statistically significant intergroup difference in sex (p
= 0.372). The four most common clinical findings in
the patient group were abdominal pain (96.5%), fever
(89.6%), leg pain (56.1%), and joint pain (54.4%). One of
the patients underwent an appendectomy.
The patients’ and controls’ demographic and
anthropometric characteristics and laboratory findings
are shown in Table 2. There were no significant intergroup
differences in mean age, weight, height, body mass index,
hemoglobin, hematocrit, or WBC or platelet counts. There
were statistically significant differences in CRP level (p =
0.001), S100A12 level (p = 0.003), and ESR (p = 0.0001)
between the FMF and control groups.
Patients were divided into attack-free period and acute
attack FMF groups. There were statistically significant
differences in the S100A12 (p = 0.027) and CRP (p =
0.001) levels between the acute attack and attack-free
period patients. The differences in WBC count (p = 0.003),
SAA level (p = 0.0001), ESR (p = 0.004), and fibrinogen
level (p = 0.001) were also statistically significant between
the attack-free period and acute attack groups (Table 3).
The attack-free period and control groups were also
compared in terms of S100A12 and other acute-phase
reactants (Table 4). Statistically significant differences were
found in CRP level (p = 0.001), S100A12 level (p = 0.030),
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Table 1. Patients’ clinical symptoms at the time of admission.
Clinical characteristics

Patients (n)

%

Male/female

31/26

54.4/45.6

Abdominal pain

55

96.5

Fever

54

94.7

Exertional leg pain

32

56.1

Arthritis/arthralgia

31

54.4

Myalgia

18

31.5

Erysipelas like erythema

8

14.0

Splenomegaly

5

8.8

Peritonitis

3

5.3

Pleuritis

2

3.5

Family history

30

52.6

and ESR (p = 0.002) between the attack-free and control
groups. On the other hand, WBC count and fibrinogen
levels did not differ significantly between the attack- free
period and control groups (p > 0.05).
Correlation tests were performed to investigate the
relationship between S100A12 level and other acute-phase
reactants in the attack-free period group, acute attack
group, and all FMF patients (Table 5). There was a positive
correlation between S100A12 and CRP levels (p = 0.002),
between S100A12 level and ESR (p = 0.001), and between
S100A12 and fibrinogen levels (p = 0.009) in all patients.
There was a positive correlation between S100A12 level
and ESR (p = 0.043) in the attack-free period group, while
there was no correlation between S100A12 level and other
acute-phase reactants in the attack group.
The receiver operating characteristic (ROC) curve was
also plotted for S100A12 and other acute-phase reactants
(Table 6, Figure). To determine the cut-off value for
S100A12, the area under the ROC curve (AUC) was 0.62
(95% confidence interval, 0.42–0.82). Similarly, AUC, cutoff value, sensitivity, and specificity values were determined
for CRP, ESR, SAA, fibrinogen, and WBC.
The genetic results of the FMF patients are shown
in Table 7. The most common mutations in our patients
were the M694V heterozygous mutation (in 26 patients)
and R202Q heterozygous polymorphism. While an
M694V mutation was seen in 35 total patients, an
R202Q polymorphism in the exon 2 MEFV gene region
was detected in 31 patients, 26 of whom (74.2%) had an
M694V mutation. The mutation analysis was negative in
one of the acute attack period FMF patient, while M694V
heterozygous and other mutations were seen in 5 patients.
There was no statistically significant difference in S100A12
between patients with or without the M694V mutation (p
= 0.866).
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Table 2. Patients’ and controls’ demographic and laboratory data.
Parameters

Patients (n = 57)
Median (min-max)

Controls (n = 31)
Median (min-max)

p

Age (years)

10 (2.5–18)

9.5 (2.5–16)

0.808

Weight (kg)

31 (13–68)

32 (13–73)

0.938

Height (cm)

135 (86–170)

135 (89–170)

0.985

WBC count (10 /mm )

8.2 (4.0–18.5)

7.26 (4.8–11.8)

0.129

CRP (mg/L)

3.6 (0.13–157.5)

0.4 (0.2–3.7)

0.001*

S100A12 (ng/mL)

435.2 (30–1644)

224.3 (20–897)

0.003*

ESR (mm/h)

26.49 (3–116)

10.74 (6–15)

0.0001*

Mean ± SD

Mean ± SD

BMI (kg/m2)

18.3 ± 3.3

17.8 ± 3.5

0.539

Hemoglobin (g/dL)

12.4 ± 1.4

12.6 ± 1.1

0.396

Hematocrite (%)

37.2 ± 3.5

37.1 ± 3.0

0.930

Platelet count (103/mm3)

298.9 ± 68.0

294.8 ± 51.9

0.772

3

3

*p < 0.05; Student t or Mann–Whitney U tests, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate,
BMI: body mass index, CRP: C-reactive protein, SD: standard deviation; WBC: white blood cell.

Patients with homozygous gene mutation for M694V
and all patients with other homozygous, heterozygous,
and compound heterozygous gene mutations were
compared in terms of S100A12 and other parameters
(Table 8). S100A12 levels were significantly higher in
M694V homozygous patients than the patients with
other mutations (p = 0.027). In addition, ESR (p = 0.001),
fibrinogen level (p = 0.001), absolute neutrophil count (p
= 0.004), and WBC count (p = 0.004) were significantly
higher in the M694V homozygous group than the patients
with other mutations.
4. Discussion
The study results showed that S100A12 protein level, ESR,
and CRP level were significantly higher in children with
FMF than in healthy controls. In addition, serum S100A12
levels were significantly higher in patients during the attack
period, as were the WBC count, CRP level, ESR, SAA level,
and fibrinogen level. Therefore, S100A12 level is a possible
marker for monitoring inflammation in FMF patients.
S100A12 is an important protein for evaluating the
activity of several inflammatory diseases. This protein is
distinctively increased in diseases such as systemic juvenile
idiopathic arthritis and FMF, although it is also elevated
in infection, malignancy, and some collagen diseases [9–
14,16,17]. In a study of 56 children and adolescents with
FMF, S100A12 levels had better indicative power than CRP
level, ESR, and SAA level. The same study demonstrated
that this protein’s level increased during the attack period
in FMF patients but decreased with colchicine treatment
and were higher in hereditary carriers without clinical

findings than in the healthy population [18]. In another
study, although S100A12 levels were higher in 29 adult
FMF patients than in healthy controls, no difference was
found in attack and attack-free FMF patients [19]. In our
study, when we compared S100A12 levels of the attack-free,
attack, and control groups, we found the highest S100A12
levels in the attack FMF group, followed by the attackfree FMF group and then the healthy controls. Although
the acute-phase markers were within normal limits in
our patients, they were higher than those in the control
group. Colchicine treatment suppresses inflammation
but is insufficient in some patients. This result indicated
that S100A12 level, ESR, and CRP level can be used in the
follow-up of such inflammation.
A comparison of attack versus attack-free patients
revealed higher S100A12 level, WBC count, CRP level,
fibrinogen level, and SAA level during FMF attack periods.
A study showed that the use of colchicine decreases even
extremely high S100A12 levels to near-normal levels after
a week of treatment [18]. In addition, FMF attacks can last
a few hours to 72 h, and the fact that the samples were not
taken during the same stage as the patients’ attack periods
may have contributed to this result.
Patients are generally asymptomatic except during
attack periods. CRP and SAA levels are elevated during
an attack, whereas ESR may not always increase [20].
However, subclinical chronic inflammation continues
during the attack-free period [21–24]. In our study,
comparison of attack-free patients with the healthy
control group revealed that CRP, S100A12, and ESR levels
were significantly higher in attack-free patients than in
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Table 3. Demographic and laboratory findings of acute attack period versus attack-free period groups.
Parameters

Attack free period (n = 43)
Median (min-max)

Acute attack period (n = 14)
Median (min-max)

p

Age (years)

10 (2.5–19)

9.7 (3.5–16)

0.662

Weight (kg)

30 (13–68)

36 (17–63)

0.738

Height (cm)

134 (86–165)

135 (103–170)

0.704

WBC count (10 /mm )

7.26 (4.8–15.8)

11.7 (4.9–18.5)

0.003*

CRP (mg/L)

1.6 (0.1–15.7)

34.9 (0.4–131.9)

0.0001*

S100A12 (ng/mL)

370 (30–1644)

634 (245–1460)

0.027*

ESR (mm/h)

14 (6–116)

40 (3–94)

0.004*

Serum amyloid A (mg/dL)

0.6 (0.1–62.0)

32.0 (0.09–138)

0.0001*

3

3

Mean ± SD

Mean ± SD

BMI (kg/m2)

18.2 ± 3.3

18,1 ± 3.3

0.650

Hemoglobin (g/dL)

12.3 ± 1.2

12.4 ± 1.9

0.774

Hematocrit (%)

36.9 ± 2.9

37.7 ± 5.0

0.853

Platelet count (10 /mm )

303.1 ± 72.2

286.0 ± 53.6

0.528

Fibrinogen (g/L)

2.6 ± 0.6

3.4 ± 0.8

0.001*

3

3

*p < 0.05; Student t or Mann–Whitney U tests, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate, BMI:
body mass index, CRP: C-reactive protein, SD: standard deviation; WBC: white blood cell.
Table 4. Demographic and laboratory findings of attack-free period versus healthy controls.
Parameters

Attack free period (n = 43)
Median (min-max)

Healthy controls (n = 31)
Median (min-max)

p

Age (years)

10.0 (2.5–19.0)

9.5 (2.5–16.0)

0.969

Weight (kg)

30.0 (13.0–68.0)

32.0 (13.0–73.0)

0.952

Height (cm)

134.0 (86.0–165.0)

135.0 (89.0–170.0)

0.902

WBC count (10 /mm )

7.26 (4.8–15.8)

7.26 (4.8–11.8)

0.446

CRP (mg/L)

1.6 (0.1–15.7)

0.4 (0.2–3.7)

0.001*

S100A12 (ng/mL)

370 (30–1644)

224.3 (20–897)

0.030*

ESR (mm/h)

14 (6–116)

10.74 (6–15)

0.002*

Parameters

Mean ± SD

Mean ± SD

Hemoglobin (g/dL)

12.3 ± 1.2

12.6 ± 1.1

0.344

Hematocrit (%)

36.9 ± 2.9

37.1 ± 3.0

0.873

303.1 ± 72.2

294.8 ± 51.9

0.498

3

3

Platelet count (10 /mm )
3

3

*p < 0.05; Student t or Mann–Whitney U tests, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate,
CRP: C-reactive protein, SD: standard deviation; WBC: white blood cell.

the control group. Although CRP levels, ESR, and SAA
levels are within normal limits in FMF carriers, S100A12
levels are higher than normal healthy individuals and pick
during attacks in patients with FMF [18,25,26]. Compared
with traditional acute-phase reagents, S100A12 levels
were higher in the silent phase of the disease [18]. These
finding show that S100A12 can be used, like ESR and CRP,
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to follow-up patients with FMF and to diagnose FMF
carriers. Taylan et al. [19] showed that S100A12, CRP, and
SAA levels were correlated with each other in attack free
period, in acute attack period of FMF and control patients.
Accordingly, correlation analyses were performed on
S100A12 and other acute-phase reactants in our study.
When all patients were considered, a positive correlation

TÜRKMENOĞLU et al. / Turk J Med Sci
Table 5. Correlation between S100A12 level and other acute-phase reactants in the attack-free
period, acute attack period, and all patients.
S100A12 (ng/mL)
All patients
(n = 57)

Parameters

Attack-free period
patients (n = 43)

Acute attack
period (n = 14)

r

p

r

p

r

p

WBC count (10 /mm )

0.195

0.146

0.044

0.788

-0.037

0.901

CRP (mg/L)

0.409

0.002*

0.092

0.559

0.313

0.275

ESR (mm/h)

0.430

0.001*

0.310

0.043*

0.476

0.085

SAA (mg/dL)

0.172

0.200

-0.027

0.866

0.018

0.951

Fibrinogen (mg/dL)

0.341

0.009*

0.115

0.463

0.382

0.177

3

3

Spearman correlation analysis, *p < 0.05, APR: acute phase reactants, WBC: white blood cell, CRP:
C reactive protein, ESR: erythrocyte sedimentation rate, SAA: serum amyloid A.

Figure. ROC curve of C reactive protein, erythrocyte sedimentation rate, S100A12 protein,
serum amyloid A, fibrinogen, white blood cell count in FMF patients.

was found between the S100A12 levels and CRP, ESR,
and fibrinogen levels. No relationship was found between
S100A12 levels and acute-phase reactants in the attack

group. On the other hand, a positive correlation was found
between S100A12 levels and ESR in the attack-free group.
Although these findings were still within normal limits,
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Table 6. Receiver operating characteristic curve analysis of acute-phase reactants in Familial Mediterranean Fever patients.

p

AUC
(Area under curve)

AUC 95% Confidence interval
Lower bound

Upper bound

CRP (mg/L)

0.0001

0.832

0.69

ESR (mm/h)

0.004

0.758

0.58

S100A12 (ng/mL)

0.049

0.620

SAA (mg/dL)

0.0001

0.825

Fibrinogen (mg/dL)

0.002

WBC count (103/mm3)

0.003

Test result variable (s)

Cut off value

Sen. %

0.97

4.80

85.7

0.94

26.5

78.6

0.42

0.82

367

64.3

0.65

1.00

8.00

85.7

0.777

0.62

0.93

2.96

71.4

0.766

0.58

0.95

8.76

78.6

AUC: Area under curve, CRP: C reactive protein, ESR: ethrytrocyte sedimentation Rate; FMF: Familial Mediterranean fever; SAA:
Serum amyloid A, Sen: sensitivity; Spe: specifity; WBC: white blood cell.
Table 7. Genetic results of familial Mediterranean fever patients.

Gene mutations

Patients
n

(%)

M694V/M694V

5

8.77

M694V/M694V and R202Q/R202Q

5

8.77

M694V/N and R202Q/R202Q

3

5.26

M694V/N and R202Q/N

16

28.07

M694V/M680I and R202Q/N

2

3.5

M694V/E167A

1

1.75

M694V/N

3

5.26

R202Q/N

5

8.76

E148Q/E148Q

1

1.75

E148Q/N

6

10.52

M680I/N

2

3.5

E726A/RS61752717

2

3.5

E167D/E148V

1

1.75

RS224205/RS2894057

1

1.75

M694I/R761H

1

1.75

F479L/E167A

1

1.75

No mutation

2

3.5

Total

57

100

especially in patients with FMF during the attack-free
period, inflammation that can be demonstrated by ESR
with S100A12 may continue.
ROC analysis evaluating S100A12 levels performed
in a study that differentiated juvenile idiopathic arthritis
patients with Kawasaki disease revealed an ROC curve
of 0.97 (95% confidence interval, 0.89–1) [27]. In our
study, when ROC analyses for patients with FMF were
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evaluated, S100A12 together with CRP, ESR, SAA, WBC,
and fibrinogen are significant in the diagnosis and followup of FMF. As a result, SAA is the best predictor among
acute-phase reactants. If the patient’s SAA value is 8.0, the
patient may be diagnosed with FMF with 85.7% sensitivity,
93% specificity, and an 82.5% probability. Similarly, if the
patient’s S100A12 value is 367, the diagnosis of FMF can
be made with 64.3% sensitivity, 72.1% specificity, and 62%
probability. Similar definitions can be made for CRP, ESR,
fibrinogen, and WBC. According to these results, S100A12
is not superior to other acute-phase reactants, but similar
to them, it can be used for diagnosis and monitoring.
Normal serum S100A12 levels are reportedly less than
120 ng/mL in healthy individuals [9,18]. However, some
individuals in our control group had above-normal levels.
S100A12 levels are known to increase in cases of infection,
malignancy, and vasculitis [10,16,17]. The control group
showed no evidence of disease. Recent studies have shown
that S100A12 levels are high in healthy carriers of FMF
[18,28]. The prevalence of FMF in our country is reportedly
1%, while 20% of its population carries the disease [3,4].
According to these results, the rate of FMF carriers may
be higher among different geographical regions. In
addition, the presence of FMF disease in the child was
initially questioned through the medical history provided
by the patient and his family, and no genetic analysis for
FMF carrier status was performed in the control group;
therefore, healthy controls with high S100A12 levels could
have been asymptomatic FMF carriers.
The most common mutation in FMF, M694V, is
considered a risk factor for amyloid formation [2–
4,6,17,18,29–31]. The MEFV gene and S100A12 activity
are expressed as increased levels of interleukin-1 cytokines
[7,8]. Interestingly, levels of this protein remain within
normal limits in Muckle–Wells and neonatal onset
multisystem inflammatory disease syndromes, which,
like FMF, exhibit inflammation through interleukin-1
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Table 8. Comparison of acute-phase reactants of patients with M694V homozygous mutation versus other
mutations.

Parameters

M694V Homozygous
(n = 10) Mean ± SD or
Median (min-max)

Other mutations
(n = 45) Mean ± SD or
Median (min-max)

p

S100A12 (ng/mL)

635 (245–1460)

370 (30–1644)

0.027*

SAA (mg/dL)

25.24 (0.64–57.80)

8.91 (0.06–138.00)

0.050

ESR (mm/h)

51.50 (15.00–116.00)

21.17 (3.00–62.00)

0.001*

CRP (mg/L)

33.06 (1.68–102.38)

13.39 (0.13–157.47)

0.081

Fibrinogen (g/L)

3.55 ± 1.03

2.65 ± 0.59

0.001*

ANC (103/mm3)

7191.00 ± 4112.59

4401.70 ± 2296.73

0.004*

Lymp. count (10 /mm )

2448.00 ± 925.09

2850.87 ± 951.00

0.228

WBC count (103/mm3)

11406.00 ± 4549.25

8194.68 ± 2711.58

0.004*

3

3

*p < 0.05; Student t or Mann–Whitney U tests, SD: standard deviation; SAA: serum amyloid A, ESR:
erythrocyte sedimentation rate; CRP: C-reactive protein, ANC: absolute neutrophil count; Lymp:
lymphocyte; WBC: white blood cell.

activity [32]. Other mechanisms that might increase
S100A12 protein levels in FMF should be considered.
In some studies of patients with FMF, S100A12 levels
were the highest in patients with M694V homozygous
or heterozygous mutations [18,19]. R202Q was the most
commonly seen polymorphism in Turkey [31]. In our
study, no significant relationship was found in the M694V
mutation analysis, and this mutation was accompanied
by the R202Q variation at a rate of 74.2%. One reason for
this may be our small sample size, or that the dosage of
colchicine therapy may differ widely in children, which has
varying effects on S100A12 levels. Another reason could
be the lack of research regarding the relationship between
R202Q variations and S100A12 protein levels.
In a study conducted by Stoler et al. [33] of 19 adult
FMF patients (four were homozygous M694V mutations),
S100A12 levels were high in those with homozygous
M694V mutations. Similar results were obtained in another
study [26]. In our study, WBC count, ESR, fibrinogen level,
and S100A12 level were higher in M694V homozygous
patients than in patients with other mutations. These results
indicate that the M694V homozygous group is at higher risk
for chronic inflammation and amyloidosis. According to
these results, the persistence of chronic inflammation and
the risk of amyloidosis are higher in M694V homozygous
patients than the other patients. We can say that an M694V
homozygous status carries a higher risk for chronic
inflammation. In addition, the higher absolute neutrophil
count, WBC count, S100A12 level, ESR, and fibrinogen
level in the M694V homozygous group indicates that these
patients are at higher risk for chronic inflammation.
Limitations of this study: The study sample was limited
in the number of patients,

especially those during the FMF attack period. In
addition, S100A12 levels were not measured in the same
patients before and after the attack period. Our patient
group received colchicine therapy, which is known to
decrease S100A12 levels. Serum samples obtained before
starting colchicine therapy could yield more accurate
results, while certain associations could be revealed
through mutation analyses.
In conclusion, here we concluded that S100A12
levels are higher in FMF patients than in the healthy
population and are higher during the acute attack than
during the attack-free period. For this reason, measuring
S100A12 levels may be helpful for diagnosing FMF and
monitoring its attacks and may be an important marker
for monitoring chronic inflammation in patients with
FMF. We found no relationship between M694V mutation
and serum S100A12 levels, but S100A12 levels were higher
in homozygous M694V mutation patients with FMF
than the patients with other mutations. Further studies
including serum S100A12 samples obtained from a larger
number of patients before colchicine therapy or samples
taken from patients who received colchicine for the same
duration could yield more accurate results regarding such
correlations.
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